Showing results (161-170 of 352) with videos related to
Sort By:
Pageof 36
Transfusion|January 30, 2009
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply marginFrancis Vekeman, Brahim K Bookhart, Joshua White, et al.Current Medical Research and Opinion|September 30, 2014
Pulse pressure and stroke risk: development and validation of a new stroke risk modelRajeev Ayyagari, Francis Vekeman, Patrick Lefebvre, et al.Current Medical Research and Opinion|January 10, 2020
Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trialAmeur M Manceur, Mike Durkin, Akshay Kharat, et al.Journal of Thrombosis and Thrombolysis|May 13, 2022
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United StatesJeffrey S Berger, François Laliberté, Akshay Kharat, et al.Current Medical Research and Opinion|October 30, 2020
Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorderMaryia Zhdanava, Harsh Kuvadia, Kruti Joshi, et al.Current Medical Research and Opinion|March 18, 2021
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US populationJeffrey S Berger, François Laliberté, Akshay Kharat, et al.Population Health Management|October 9, 2019
Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?Dominic Pilon, Antoine C El Khoury, Ameur M Manceur, et al.Current Medical Research and Opinion|February 8, 2023
Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumabMaryia Zhdanava, Zhijie Ding, Ameur M Manceur, et al.Journal of Managed Care & Specialty Pharmacy|June 20, 2020
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical ConditionsMaryia Zhdanava, Harsh Kuvadia, Kruti Joshi, et al.Journal of Comparative Effectiveness Research|August 11, 2021
Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacyFrançois Laliberté, Veronica Ashton, Akshay Kharat, et al.Pageof 36